Introduction {#Sec1}
============

Surgery of the thoracic aorta is life-saving, although not without risks. Besides the surgical risk of major bleeding, devastating central nervous system (CNS) complications in the form of stroke or paraplegia are not uncommon.

There has been a rapid development of endovascular surgical approaches of correcting thoracic aortic disease during the recent decade \[[@CR7]\]; however, in situations of complex pathology that affects the arch vessels, open surgery with hybrid approaches are perhaps the currently most preferred \[[@CR28]\].

Apart from the risk of disturbing the cerebral circulation during reconstruction of the arch vessels, there is also a risk of disrupting the spinal blood flow during surgery of the arch and descending aorta. There exist a number of adjunct therapies that can be undertaken with the aim to prevent spinal injury, including elevated perfusion pressures, moderate/deep hypothermia, placement of intrathecal drainage, perioperative neurophysiologic monitoring, and to surgically avoid compromising more than one vascular territory that supplies the spinal cord (subclavian-intercostal-lumbar) \[[@CR13], [@CR17], [@CR23], [@CR34]\].

Early detection of CNS symptoms with subsequent intervention can potentially prevent injury from becoming manifest, for instance by elevating perfusion pressure or lowering intracranial/spinal pressure (ICP). It is therefore of essence to detect changes immediately \[[@CR13]\]. However, these patients are often circulatory unstable in the initial phase after surgery, which makes it unsuitable to move them for radiological imaging. Furthermore, radiological exams early after ischemic injury may be unreliable \[[@CR11]\]. The patients are most often intubated and thereby sedated for many hours after surgery, sometimes even days, which makes clinical examinations challenging. These factors taken together make it difficult to detect, let alone intervene against ischemic injury.

For many acute \[[@CR4]\] and chronic \[[@CR3], [@CR32]\] neurological diseases, establishment of biomarkers has allowed improvement of diagnose and prediction of disease course, but biological markers are under-developed for patients undergoing aortic surgery. In the current study, we studied serum and cerebrospinal protein profiles in patients operated on the thoracic aorta, where a significant risk of developing neurologic injury was present. The protein analysis was directed against neuronal-related proteins with the aim to identify new markers of value in the perioperative care of this group of patients.

Methods {#Sec2}
=======

Patients {#Sec3}
--------

All patients with pathology of the thoracic aorta operated at the Department of Cardiothoracic Surgery and Anesthesia at Uppsala University Hospital, with substantial risk for developing SCI, and who consented to having a spinal drain were after informed written consent included in the study. All patients consented to having the intrathecal catheter placed, in the evening before surgery, but in three patients, this was not successful. The drainage was set to automatically drain if ICP was over 10-cm H~2~O.

Surgery {#Sec4}
-------

Four patients were operated with posterolateral thoracotomy, whereof one patient was closed without further procedure, i.e., only exploratory. The three patients that were operated were so using standard woven grafts with partial bypass, with femoral cannulation and extra-corporeal perfusion of the lower body, at 34 or 35 °C.

One patient was operated with a supracoronary woven graft, via median sternotomy and hemi-arch reconstruction using retrograde cerebral perfusion and moderate to deep hypothermia (21 °C). Sixteen patients were operated with Frozen Elephant Trunc (FET) grafts; 7 E-vita (Jotec, Hechingen, Germany) and nine thoraflex hybrid (Vascutec, Terumo, Renfrewshire, Scotland). These were all operated with a median sternotomy and selective antegrade cerebral perfusion with circulatory arrest and moderate hypothermia (20--25 °C). Nine out of the 16 FET patients (56.3%) were preoperatively deviated with the left subclavian artery transposed to the left carotid artery. The innominate and left carotid artery were re-implanted in all cases perioperatively into the FET graft. In the seven none-deviated subclavian arteries, the left subclavian artery was reimplanted in the FET graft in 2 (12.5%) cases, whereas it was ligated perioperatively in five patients (31.3%). This means that 11 of 16 FET patients (68.8%) had the left subclavian reconnected.

Two patients were operated with TEVAR, with covered stent grafts in the descending aorta (Gore Tag, 34 × 100 mm in one patient and two grafts 31 × 150 and 37 × 200 mm in the other patient). Both were deemed at risk of SCI as one had a long section of the aorta stented, and the other patient had several stent grafts earlier in the descending aorta with leakage in-between the grafts. These patients are included in the clinical outcomes, but not in the postoperative protein analysis, see below.

Sample Preparation {#Sec5}
------------------

Both serum and cerebrospinal fluid (CSF) samples were obtained preoperatively and at 8 am in the first and second postoperative mornings. See [Supplementary data](#Sec24){ref-type="sec"} for details.

Clinical Data {#Sec6}
-------------

The clinical data of the patients is summarized in Tables [1](#Tab1){ref-type="table"}, [2](#Tab2){ref-type="table"} and [3](#Tab3){ref-type="table"} and described in the [Supplementary data](#Sec24){ref-type="sec"}.Table 1Preoperative clinical data of the patientsPatients (*n* = 23)Mean age (SD), year59.8(11.6)*n*%Sex Male1878.3 Female521.7Hypertension Yes2295.7 No14.3Diabetes Yes417.4 No1982.6COPD Yes521.7 No1878.3EF \> 451982.6 30--45417.4 \< 3000Class of heart failure NYHA I313.0 NYHA II939.1 NYHA IIIa521.7 NYHA IIIb14.3 N/A521.7Previous cardiac surgery Yes1043.5 No1356.5Absolute GFR (Lund-Malmö) Normal (GFR \> 85)834.8 Moderate (50--85)1252.2 Severe (\< 50)313.0COPD: chronic obstructive pulmonary disease, EF: ejection fraction, NYHA: New York Heart Association, GFR: glomerular filtration rateTable 2Perioperative clinical data of the patients*n*%Diagnose Acute type-A aortic dissection28.7 Chronic type-A aortic dissection834.8 Chronic type-B aortic dissection417.4 Aortic aneurysm939.1Type of procedure FET1669.6 TEVAR28.7 Woven graft ascending aorta14.3 Woven graft descending aorta313.0 Exploratory Thoracotomy14.3Preoperative subclavia deviation Yes939.1 No1460.9Spinal drain2087.0Heart valve surgery521.7CABG00Dimension of aorta Mean (SD), mm62.8(10.7)ECC-time (minutes) Mean duration (*n* = 20)293.4 Mean aortic cross-clamp (*n* = 17)148.7CABG, coronary artery by-pass grafting; ECC, extra-corporeal circulation; FET, frozen elephant trunk; TEVAR, thoracic endovascular aortic repairTable 3Postoperative clinical data of the patients*n*%30-Day mortality00Deceased (within follow-up)28.6Neurological sequelae Total1460.9 Spinal cord injury313.0 Delirium834.8 Hallucination939.1Reoperation Total730.4 Bleeding521.7 Cardiac tamponade28.7 Infection00 Dialysis28.7 Atrial fibrillation1252.2 Pleural drainage313.0 Pericardiocentesis14.3 Stroke00 Postlumbar puncture headache418.2

Protein Measurements {#Sec7}
--------------------

The levels of 92 proteins with relevance to neurology were measured simultaneously by multiplex proximity extension assay (PEA). The assay was performed according to the manufacturer's recommendations ([www.olink.com](http://www.olink.com)). See [Supplementary data](#Sec24){ref-type="sec"} for details.

Statistics {#Sec8}
----------

Among the serum and CSF samples from 23 patients, postoperative samples from three patients were removed for analysis because two had endovascular treatment and one patient only underwent explorative thoracotomy. These were excluded as the use of extracorporeal circulation and the much more extensive surgery in remaining patients had such a profound biochemical impact, which made comparisons unjustifiable. One postoperative serum sample was excluded, since the levels of all the proteins in this sample were highly aberrant from the other samples, most likely due to technical reasons at sampling. Among the 92 proteins included in the panel, five were excluded due to suspected antibody cross-activity. Another 21 proteins were excluded because the detectable percentages of these proteins were less than 50% in both serum and CSF samples in all the pre- and postoperative groups, including CX3CR1, DCLK1, HES1, HOXB1, JAG1, KLF4, MAPT, MSI2, NES, NGFR, NOG, OLIG2, PTCH1, RTN4RL1, S100B, SLC1A3, SOX1, SOX5, SOX11, SOX21, and TPH1 (Table [S1](#MOESM1){ref-type="media"}). An individual assessment of these 21 proteins, verified that in 20 of 21 cases, the levels were low in all samples. However, CX3CR1 differed and the levels were low in general, but were to a higher degree detectable in the patients with postoperative SCI (Fig. [S2](#MOESM1){ref-type="media"}). In summary, 66 proteins in 59 serum and 50 CSF samples were included in the finals analysis.

In general, the groups were small, especially those with neurological complications. Therefore, for the analysis of protein levels in the patients with neurological complications, postoperative days 1 and 2 were clustered together in the patients that either developed neurological complications and those that did not.

Differences in pre- and postoperative protein levels were tested by non-parametric Mann-Whitney *U* test. False discovery rate (FDR) was applied to adjust for multiple testing. A *p* value smaller than 0.05 (two-tailed) was considered as significant. Data analysis and interpretation were performed in R software ([www.r-project.org](http://www.r-project.org)). The exact *p* values are for clarity shown in the tables and not in the individual graphs.

To verify the consistency and assess potential intraassay variability, several samples were run in duplicates and the correlation coefficient analyzed with Pearson's test. The *r* values were between 0.996 and 0.998, indicating a high reproducibility of the assay (data not shown).

Study Approval {#Sec9}
--------------

The study was approved by the local ethical committee (Regionala Etikprövningsnämnden i Uppsala) under permit number 2012/296.

Results {#Sec10}
=======

Patient Characteristics Preoperatively {#Sec11}
--------------------------------------

Twenty-three patients were included during a period of 39 months. Mean follow-up was 38 months (range 18 to 58). The mean age was 59.8 years (± 11.6 SD), although the distribution spread over a range from 26 to 77 years. The included diagnoses were two acute type-A dissections, eight chronic type-A dissections, four chronic type-B dissections, and nine aneurysms. The mean maximum dimension of the aorta was 63 ± 11 mm.

Two patients were operated with TEVAR of the descending aorta, 16 patients with frozen elephant trunk (FET), four patients with standard woven vascular grafts (one ascending/three descending), and one patient was only operated with an exploratory thoracotomy, and then closed due to porcelain aorta. In three patients (13%), it was not possible to place a spinal drain; nine patients, all candidates for FET (39% of all patients, 56% of the FET), were preoperatively deviated from the left carotid to subclavian artery.

All patients but one had hypertension (96%), 12 (52%) were or had been smokers, and four (17%) had reduced left ventricular function (LVEF 30--45%). Ten (44%) had previous cardiac surgery with opened pericardium. Twelve patients (52%) had moderately reduced renal function (GFR 50--85 ml/min) and three (13%) had markedly reduced renal function (GFR \< 50 ml/min). See Tables [1](#Tab1){ref-type="table"} and [2](#Tab2){ref-type="table"} for details.

Postoperative Data {#Sec12}
------------------

### General Parameters {#Sec13}

There was no 30-day mortality; however, two patients died during follow-up, both FET operated, one 7 months postoperatively, and one 17 months postoperatively. The causes of death were aortic rupture distal to the thoraflex graft and multi-organ failures after graft infection in the thoracoabdominal endovascular stent grafts used in the extension of the FET graft, respectively. The mean ECC (extracorporeal circulation) time was 293.4 min, and the mean aortic cross-clamp time was 148.7 min. The mean amount of blood products used intraoperatively was 1990-ml packed red blood cells, 1780-ml fresh frozen plasma, and 950-ml platelet concentrate. Seven patients (30%) were re-operated for bleeding or tamponade and one (4.3%) required pericardiocentesis; no patients were re-operated for infection. Two patients (8.7%) required postoperative dialysis. Atrial fibrillation was common, 12 patients (52%). See Table [3](#Tab3){ref-type="table"} for details.

### Neurological Complications {#Sec14}

Three patients suffered ischemic spinal cord injury (SCI; 13%), although one patient was paraparetic before start of operation (acute type-A dissection), so only two were related to the surgery (8.7%), one open descending operation, and one FET (who did not have a deviated subclavia). Eight patients (35%) developed delirium, nine patients (39%) had hallucinations, and four (18%) developed spinal headache. No patients developed stroke. A few patients had more than one neurological complication. In summary, 14 patients (60.9%) suffered from any type of the above-mentioned neurological complication postoperatively. See Table [3](#Tab3){ref-type="table"} for details.

Biochemical Data {#Sec15}
----------------

As expected, there was an obvious difference of protein profiles between serum and CSF, as shown in principal component analysis and heatmap (Fig. [S1](#MOESM1){ref-type="media"}a and b). Levels of 50 out of 66 proteins were significantly different after *p* values adjusted with 5% FDR or 40 after Bonferroni correction for multiple testing (*p* \< 0.05/60) (Table [S2](#MOESM1){ref-type="media"}a and b).

There were also large differences between the preoperative and postoperative protein profiles in the patient population as a whole (Fig. [1](#Fig1){ref-type="fig"}). As the focus of the current study was on the patient group with neurological complications, no further description of the general patient population is given here, but can be found in the [Supplementary data](#Sec24){ref-type="sec"}.Fig. 1The proteins differing most significantly in serum (**a**--**e**) and CSF (**a**, **b**, **f**--**h**) postoperatively compared with preoperatively. D0 = preoperatively, D1 = postoperative day 1, D2 = postoperative day 2. NPX S/N: normalized expression as explained in methods. N = serum; D0:22, D1:19, D2:18, CSF; D0:20, D1:15, D2:15

### Patients with Postoperative Spinal Cord Injuries {#Sec16}

There were few samples from patients with SCI, but the levels of 15 proteins differed between the injured and non-injured patients in serum at unadjusted *p* \< 0.05 and 4 at *p* \< 0.01; CHI3L1, VIM, IL6, and GFAP (Fig. [2](#Fig2){ref-type="fig"}a--d, Table [4](#Tab4){ref-type="table"}). However, no protein was significant between the injured and non-injured patients after FDR correction (Table [4](#Tab4){ref-type="table"}).Fig. 2The proteins differing most significantly in serum (**a**--**e**) and CSF (**e**--**j**) in the patients that suffered postoperative spinal cord injury (SCI) compared to those that did not postoperatively. NPX S/N: normalized expression as explained in methods. D0_neg = preoperative levels in patients with no postoperative injury, D0_pos = preoperative levels in patients postoperatively injured, D1 + D2_neg = all patients that did not suffer SCI postoperatively. D1 + D2_pos = all patients that suffered SCI postoperatively. N = CSF: D0_neg:18, D0_pos:2, D1 + D2_neg:26, D1 + D2_pos:4, Serum n = D0_neg:21, D0_pos:1, D1 + D2_neg:35, D1 + D2_pos:2Table 4Spinal cord injuries, postoperative levels non-injured compared with injured, serumSerum proteinmean ± SD_D1 + D2_negmean ± SD_D1 + D2_posmean_D1 + D2 pos_D1 + D2 negP_D1 + D2 neg vs. D1 + D2 posFDR~adj~ P_D1 + D2 neg vs. D1 + D2 posCHI3L18.06 ± 0.86.37 ± 0.1− 1.695050.00300.0661IL68.01 ± 1.210.81 ± 0.42.7974830.00300.0661VIM5.73 ± 0.66.91 ± 0.21.1788420.00300.0661GFAP0.04 ± 0.10.63 ± 0.20.5934040.00410.0684SIRT24.25 ± 0.96.51 ± 12.2583250.01200.1014CDCP13.95 ± 0.65.14 ± 0.11.1916320.01200.1014MMP26.13 ± 0.26.53 ± 0.10.3967630.01200.1014GAD20.09 ± 0.20.52 ± 00.431720.01230.1014GMFB0.1 ± 0.20.84 ± 0.10.7426810.01480.1083PMP21.69 ± 1.14.52 ± 0.72.8261570.02440.1372MGMT4.71 ± 1.26.73 ± 0.62.0252620.02700.1372ITGA22.33 ± 0.32.94 ± 0.40.6105130.02700.1372CSPG40.64 ± 0.31.07 ± 0.10.4292150.02700.1372DLL110.9 ± 0.411.34 ± 00.438280.04800.2114PXN3.46 ± 0.74.42 ± 0.10.9625610.04800.2114D0: preoperatively; D1 + D2: postoperative day 1 and postoperative day 2 combined; neg: no spinal cord injury; pos: spinal cord injury; FDR: false discovery rate

The levels of two proteins, IL6, and GFAP differed in CSF between patients with and without SCI at uncorrected *p* \< 0.05, whereas none was significant after FDR correction (Fig. [2](#Fig2){ref-type="fig"}b, d, Table [5](#Tab5){ref-type="table"}). IL6 was however clearly raised in the injured patients postoperatively compared to baseline also after *p* value correction (Fig. [2](#Fig2){ref-type="fig"}b, Table [S3](#MOESM1){ref-type="media"}d). CX3CR1 showed an interesting pattern, with increased levels in the CSF of the injured compared to the non-injured postoperatively, but this did not quite reach statistical significance (Fig. [S2](#MOESM1){ref-type="media"}).Table 5Spinal cord injuries, postoperative levels non-injured compared with injured, CSFCSF proteinmean ± SD_D1 + D2_negmean ± SD\_\
D1 + D2_posmean\_\
D1 + D2 pos -- D1 + D2 negP_D1 + D2 neg vs. D1 + D2 posFDR~adj~ P_D1 + D2 neg vs. D1 + D2 posIL66.07 ± 1.57.97 ± 1.11.900.01760.9072GFAP1.15 ± 0.63.23 ± 22.080.04440.9072D0: preoperatively; D1 + D2: postoperative day 1 and postoperative day 2 combined; neg: no spinal cord injury; pos: spinal cord injury; FDR: false discovery rate

### Patients with Postoperative Delirium {#Sec17}

For delirium, the levels of three proteins differed in serum of affected compared to non-affected patients at uncorrected *p* \< 0.01 (TR4, EZH2, and SOX10) and 15 at *p* \< 0.05 (Fig. [3](#Fig3){ref-type="fig"}a--c, Table [6](#Tab6){ref-type="table"}). TR4 and EZH2 were still significantly higher in patients with postoperative delirium compared to those without after FDR correction (Table [6](#Tab6){ref-type="table"}). Interestingly, TR4 and EZH2 differed already preoperatively in the patients that developed delirium after operation (Fig. [3](#Fig3){ref-type="fig"}a--b). Five proteins (CHI3L1, IL6, SFRP2, PMP2, and RTN4R) differed in serum in patients with postoperative delirium compared to baseline with corrected *p* \< 0.01 and 11 at *p* \< 0.05 (Table [S4](#MOESM1){ref-type="media"}c).Fig. 3The proteins differing most significantly in serum (**a**--**c**) and CSF (**d**--**f**) in the patients that suffered postoperative delirium compared to those that did not postoperatively. NPX S/N: normalized expression as explained in methods. D0_neg = preoperative levels in patients with no postoperative delirium, D0_pos = preoperative levels in patients with postoperative delirium, D1 + D2_neg = all patients that did not suffer delirium postoperatively. D1 + D2_pos = all patients that suffered delirium postoperatively. N = CSF: D0_neg:14, D0_pos:6, D1 + D2_neg:18, D1 + D2_pos:12, Serum n = D0_neg:15, D0_pos:7, D1 + D2_neg:24, D1 + D2_pos:13Table 6Delirium, postoperative levels non-injured compared with injured, serumSerum proteinmean ± SD_D1 + D2_negmean ± SD_D1 + D2_posmean_D1 + D2 pos_D1 + D2 negP_D1 + D2 neg vs. D1 + D2 posFDR~adj~ P_D1 + D2 neg vs. D1 + D2 posTR40.13 ± 0.20.89 ± 0.70.760.00000.0011EZH20.19 ± 0.30.76 ± 0.40.570.00020.0050SOX100.09 ± 0.20.3 ± 0.30.210.00760.1662SMAD90.21 ± 0.20.49 ± 0.30.280.01050.1738IL1B0.16 ± 0.40.24 ± 0.30.080.01700.1890IQGAP10.16 ± 0.20.55 ± 0.50.390.02120.1890GMFB0.09 ± 0.20.23 ± 0.20.140.02600.1890CC20.17 ± 0.20.4 ± 0.30.230.02630.1890BMI10.07 ± 0.10.24 ± 0.20.170.02980.1890BMPR1B0.12 ± 0.20.22 ± 0.20.100.03350.1890SFRP22.8 ± 0.63.17 ± 10.370.03900.1890SOX20.07 ± 0.10.26 ± 0.30.190.03950.1890FABP70.02 ± 0.10.1 ± 0.10.090.04070.1890GAD20.08 ± 0.20.19 ± 0.20.110.04280.1890PTCh20.1 ± 0.10.18 ± 0.10.080.04300.1890D0: preoperatively; D1 + D2: postoperative day 1 and postoperative day 2 combined; neg: no delirium; pos: delirium; FDR: false discovery rate

Only one protein, KLF6, differed between the postoperative CSF levels in patients with and without delirium at uncorrected *p* \< 0.05 (Fig. [4](#Fig4){ref-type="fig"}d, Table [7](#Tab7){ref-type="table"}). IL6, GFAP, CX3CL1, and ICAM1 were significantly increased compared to preoperatively in the patients with postoperative delirium (Table [S4](#MOESM1){ref-type="media"}d), and CHI3L1 and VIM were significantly decreased postoperatively in the patients with delirium compared to preoperatively, but only IL6 significantly rose in the patients without delirium compared to preoperatively (Table [S4](#MOESM1){ref-type="media"}b and d).Fig. 4The proteins differing most significantly in serum (**a**--**b**) and CSF (**c**--**f**) in the patients that suffered postoperative hallucinations compared to those that did not postoperatively. NPX S/N: normalized expression as explained in methods. D0_neg = preoperative levels in patients with no postoperative hallucinations, D0_pos = preoperative levels in patients with in patients with postoperative hallucinations, D1 + D2_neg = all patients that did not suffer hallucinations postoperatively. D1 + D2_pos = all patients that suffered hallucinations postoperatively. N = CSF: D0_neg:11, D0_pos:9, D1 + D2_neg:12, D1 + D2_pos:18, Serum n = D0_neg:13, D0_pos:9, D1 + D2_neg:20, D1 + D2_pos:17Table 7Delirium, postoperative levels non-injured compared with injured, CSFCSF proteinmean ± SD\_\
D1 + D2_negmean ± SD_D1 + D2_posmean_D1 + D2 pos\_ D1 + D2 negP_D1 + D2 neg vs. D1 + D2 posFDR~adj~ P_D1 + D2 neg vs. D1 + D2 posKLF60.16 ± 0.20.34 ± 0.20.180.02270.8779D0: preoperatively; D1 + D2: postoperative day 1 and postoperative day 2 combined; neg: no delirium; pos: delirium; FDR: false discovery rate

### Patients with Postoperative Hallucinations {#Sec18}

For hallucinations, two proteins differed in serum of affected compared to non-affected patients at uncorrected *p* \< 0.01 (NF1 and MGMT) and 11 at *p* \< 0.05 (Fig. [4](#Fig4){ref-type="fig"}a, b, Table [8](#Tab8){ref-type="table"}). Only NF1 was still significantly higher in patients with hallucinations after FDR correction (Table [8](#Tab8){ref-type="table"}). Compared to baseline, 16 proteins were significantly different at *p* \< 0.01 in the patients with postoperative hallucinations, while 26 differed at *p* \< 0.05 (Table [S5](#MOESM1){ref-type="media"}c).Table 8Postoperative levels in patients with and without postoperative hallucinations, serumSerum_proteinmean ± SD_D1 + D2_negmean ± SD_D1 + D2_posmean_D1 + D2 pos_D1 + D2 negP_D1 + D2 neg vs. D1 + D2 posFDR~adj~ P_D1 + D2 neg vs. D1 + D2 posNF14.23 ± 1.26.01 ± 1.31.780.00010.0059MGMT4.29 ± 1.45.44 ± 0.81.150.00250.0832SLIT20.21 ± 0.30.38 ± 0.30.160.01080.1833CAMK2G0.07 ± 0.10.17 ± 0.10.100.01110.1833CSPG40.58 ± 0.30.76 ± 0.20.190.01690.2227VIM5.57 ± 0.76.06 ± 0.60.490.02190.2244SFRP22.65 ± 0.83.26 ± 0.60.610.02380.2244NOTCH40.4 ± 0.20.7 ± 0.40.290.04170.2533FZD20.28 ± 0.30.53 ± 0.40.250.04230.2533FN10.78 ± 0.40.5 ± 0.4− 0.280.04590.2533MMP26.09 ± 0.26.22 ± 0.20.130.04850.2533D0: preoperatively; D1 + D2: postoperative day 1 and postoperative day 2 combined; neg: no hallucinations; pos: hallucinations; FDR: false discovery rate

Only the levels of CC2 differed in CSF between patients with and without postoperative hallucinations at uncorrected *p* \< 0.01 and 11 proteins at *p* \< 0.05, but none were significant after FDR correction (Fig. [4](#Fig4){ref-type="fig"}c, Table [9](#Tab9){ref-type="table"}). IL6, VIM, GFAP, and CHI3L1 differed in the patients with hallucinations after surgery compared to preoperatively (Table [S5](#MOESM1){ref-type="media"}d), and 14 differed in the patients without postoperative hallucinations compared to preoperatively, after FDR correction (Table [S5](#MOESM1){ref-type="media"}b). These patients are further described in the [supplementary data](#Sec24){ref-type="sec"}.Table 9Postoperative levels in patients with and without postoperative hallucinations, CSFCSF_Proteinmean ± SD_D1 + D2_negmean ± SD_D1 + D2_posmean_D1 + D2 pos_D1 + D2 negP_D1 + D2 neg vs. D1 + D2 posFDR~adj~ P_D1 + D2 neg vs. D1 + D2 posCC20.15 ± 0.20.04 ± 0.1− 0.110.00820.2835IL1B0.43 ± 1.20 ± 0− 0.430.01300.2835NOTCH40.12 ± 0.10.04 ± 0.1− 0.080.01370.2835BMI10.17 ± 0.10.08 ± 0.1− 0.080.01800.2835FZD40.66 ± 0.20.48 ± 0.2− 0.180.02460.2835ITGA20.51 ± 0.20.37 ± 0.2− 0.140.03100.2835PXN0.81 ± 0.70.35 ± 0.4− 0.460.03410.2835MGMT1.52 ± 10.87 ± 0.6− 0.650.03870.2835BMPR1B0.51 ± 0.20.34 ± 0.2− 0.170.03870.2835TWIST20.37 ± 0.30.21 ± 0.3− 0.160.04460.2872GAD21.02 ± 0.80.58 ± 0.3− 0.450.04790.2872D0: preoperatively; D1 + D2: postoperative day 1 and postoperative day 2 combined; neg: no hallucinations; pos: hallucinations; FDR: false discovery rate

Discussion {#Sec19}
==========

In the current study, we present clinical and biochemical data from a cohort operated for complex disease in the thoracic aorta where the surgery entails substantial risks for neurological complications. To our knowledge, the study is the first that describes an extensive protein analysis of both serum and CSF. The findings can aid to identify specific biomarkers of neurologic injury in this patient category.

Clinical Results {#Sec20}
----------------

Neurological complications of any sort were common in our material (61%), but the spectrum of severity was wide, where SCI is the most devastating. SCI related to the surgery occurred in 8.7% in our material, which is comparable with incidences in other studies \[[@CR13]\]. Other comorbidities, such as atrial fibrillation and delirium, were frequent.

Biomarker Profiling---General Results of Surgery {#Sec21}
------------------------------------------------

There were large differences in the postoperative compared to preoperative protein profiles in both serum and CSF. This is not surprising as the surgery itself triggers a systemic response. Some markers, like IL6 were strongly increased in both serum and CSF postoperatively, whereas others, like VIM showed different patterns in CSF (decreased) and in serum (increased) postoperatively. No further analysis was performed on the samples in the group as a whole, as was on the patient group with neurological complications.

Specific Analysis of the Patients with Neurological Complications {#Sec22}
-----------------------------------------------------------------

Biomarkers after traumatic spinal cord injury are fairly well developed \[[@CR2], [@CR12]\]. However, biomarkers for SCI after aortic surgery are not as well-established, although some exist, where rises in intrathecal lactate is an early sign of spinal cord ischemia \[[@CR8], [@CR18]\]. Also, S100b increases intrathecally after spinal cord ischemia, but this takes longer, up to 6 h \[[@CR18]\]. However, increases in S100b cannot distinguish between spinal cord or brain injuries \[[@CR27]\].

IL6 is a proinflammatory cytokine, abundant in most organ systems, and GFAP (glial fibrillary acidic protein) is a structural protein in astrocytes. They both exhibited the same trend as the levels were increased postoperatively in all patients, but more so in SCI patients. This makes both IL6 and GFAP less useful as specific markers for SCI, although perhaps a threshold for increased risk of negative outcome could be identified. Increased levels of IL6 in blood have been linked to worse outcome after stroke \[[@CR6]\], but the authors conclude, as we do, that the clinical usefulness may be small, since this again may be a question of cutoff levels.

In another study of open thoraco-abdominal aortic aneurysm (TAAA) surgery increased GFAP levels postoperatively were associated with delayed onset of paraplegia \[[@CR35]\]. But the conclusion was that the usefulness of biomarkers in predicting SCI was limited, as the levels rose only after the injury had occurred.

It is worth mentioning that there are several interesting proteins that displayed alterations in the injured population compared to the non-injured, but failed to reach statistical significance, in the limited number of samples. CX3CR1 a chemokine receptor on microglia, \[[@CR14]\], initially excluded from the analysis (see methods), showed a strong tendency of increase in the CSF of the SCI patients compared to the non-injured postoperatively (*p* = 0.14). This is interesting as blocking of CX3CR1 signaling leads to improved outcome after traumatic SCI in mice \[[@CR14]\]. CSPG4 showed increases in serum of the injured compared to the non-injured postoperatively (*p* = 0.027 unadjusted and *p* = 0.14 FDR adjusted) and may turn out to be a candidate in future studies. CSPG4 (chondroitin sulphate proteoglycan 4, also called NG2) is a part of the extracellular matrix and has been studied in the context of traumatic SCI \[[@CR5]\]. NG2/CSPG4 is believed to be detrimental and disturb axonal regeneration after traumatic SCI, as inhibition of NG2 with antibodies leads to increased axonal regeneration \[[@CR31]\].

In a mixed cardiac surgery population, about 25% suffer postoperative delirium although the range is wide, from 10 to 80% in different settings \[[@CR16]\]. Delirium is a potentially severe complication in itself and often necessitates extended ICU-care, but is also a risk for other complications, such as sepsis and sternal instability \[[@CR16]\]. Delirium is also associated with long-term cognitive decline and mortality \[[@CR9]\]. With respect to aortic surgery, circulatory arrest time influences delirium development negatively and hypothermia, although protective in a general brain perspective, also increases the risk for delirium \[[@CR16]\].

Protein biomarkers for delirium after cardiac surgery have been studied to some extent, but no marker has emerged as optimal with regard to specificity or predictive value. Hermann et al. assessed serum levels of NSE and S100b after cardiac surgery and found that increased levels accurately predicted both postoperative delirium and also neurobehavioral outcome up to 6 months after surgery \[[@CR15]\]. In line with this, low levels of S100b rule out delirium, although in an off-pump CABG setting \[[@CR1]\]. However, neither S100b nor NSE is specific for delirium.

In CSF, KLF6 (Kruppel-like factor-6) was elevated in patients with delirium. KLF6 is a transcriptional activator involved in oligodendrocyte development and myelination processes \[[@CR19]\] as well as in axonal growth \[[@CR30]\], and levels of KLF6 are modified by miRNA after nerve injury in mice \[[@CR21]\].

Both TR4 and EZH2 were elevated in serum in the patients with postoperative delirium; however, the patients that developed postoperative delirium had elevated levels of both TR4 and EZH2 already preoperatively. TR4 and EZH2 could therefore be interesting candidates to predict risk of developing postoperative delirium. EZH2 (enhancer of zeste homolog 2) has been linked to neurodegenerative disorders \[[@CR20]\] as well as to learning and memory, thus linking it to cognition \[[@CR37]\]. TR4 (testicular receptor 4) has a role in myelination and oligodendrocyte maturation \[[@CR36]\] and maintenance of spinal interneurons \[[@CR33]\]. The physiological link between TR4 and delirium is not evident, but disturbed interneuron signaling leads to distorted sensory input \[[@CR36]\].

Hallucinations may be a part of the delirium state, but also manifests in patients that are otherwise orientated. Apart from being highly unpleasant, it sometimes needs to be treated with neuroleptics, which are not without side effects. NF1 (neurofibromin 1), associated with neurofibromatosis type 1, has been linked to cognitive impairments \[[@CR24]\], differed in the patients with and without hallucinations. The fact that there were discrete markers that differed between patients with delirium and hallucinations supports the notion that these are two different cognitive disturbances.

Postspinal puncture headache is a relatively minor complication in the setting of extensive aortic surgery. Nonetheless, it commonly occurs in almost one of five TAAA patients with spinal drain \[[@CR26]\], and it can lead to significant morbidity, which often necessitates active treatment \[[@CR26]\]. It would be of interest to verify the identified markers further in other spinal headache populations.

An optimal biomarker should be both sensitive and specific. In our study, this would mean that levels should be altered in the injured group compared to the non-injured group postoperatively (D1 + D2_pos vs. D1 + D2_neg), but at the same time not altered between the preoperative group compared to the non-injured postoperative group. Serum CSPG4 and MGMT, as well as CSF CX3CR1, are such candidates in SCI, but after adjustment, the statistical significance disappeared in the limited patient material investigated herein.

Ideally, the results of the current study can contribute to improved, early diagnostics, and consequent treatment of neurological complications after thoracic aortic surgery, which would be of great clinical relevance. Especially prevention of manifest SCI would be of outmost value, as ischemic spinal injuries show poor prognosis with regard to recovery in spite of long rehabilitation \[[@CR22]\]. Before clinical application of the current results further confirmation is warranted, especially for the small SCI group. However, the results already suggest that TR4 and EZH2 levels could be used to preoperatively identify patients that are at risk of developing postoperative delirium. For a summary of the markers of greatest interest, see Table [10](#Tab10){ref-type="table"}.Table 10Summary of most interesting proteinsProteinConditionTissue/fluidStatus in affectedFunctionUsefulness in current settingIL6SCICSF and SerumIncreasedPleiotropic cytokine, wide range of effectsUnspecific in this setting, perhaps cut-off levels exist?GFAPSCICSF and SerumIncreasedStructural protein in astrocytesUnspecific in this setting, perhaps cut-off levels exist?CSPG4SCISerumIncreased\*Matrix growth, disturbed axonal regenerationNeutralizing antibodies existCX3CR1SCICSFIncreased\#Chemokine receptor on microgliaDeletion improves outcome after SCI in miceKLF6DeliriumCSFIncreasedMyelination, axonal growth, glioblastomasLevels modifiable with miRNA?TR4DeliriumSerumIncreasedInterneuron maintenance, oligodendrocyte maturationPredict development of delirium?EZH2DeliriumSerumIncreasedNeural progenitor development, memory and learningPredict development of delirium?NF1HallucinationsSerumIncreasedNeurofibromatosis, linked to cognitive impairmentsImproved diagnostics and disease understanding?\*Not significant after FDR adjustment (*p* = 0.012 unadjusted and *p* = 0.10 FDR adjusted)\#Not significant, *p* = 0.14

When interpreting biomarkers, it is also important to remember the basic pathophysiology and not over-interpret potential variances in protein levels as causative mechanisms. For instance in the setting of SCI, as compared to perhaps delirium and hallucinations, there is most often a distinct surgical/mechanic explanation, with disturbed blood-flow as a causative mechanism. Delirium and hallucinations may manifest their causation more at the microscopic/neurochemical and perhaps individual level. Nonetheless, early postoperative detection would be of large value for all aforementioned conditions.

Serum samples are more easily available than CSF samples and for that reason preferable as biomarkers. However, CSF samples could provide further information and may mirror the CNS compartment better than serum, potentially reflecting pathology earlier. However, this cannot be concluded from our studies, as no CSF samples were available from earlier than the first postoperative morning, and at this time, many changes were already detectable in serum. Perhaps CSF samples taken perioperatively or in the first hours postoperatively could be more sensitive in identifying neurological alterations, and this may be worth exploring further.

A related question concerns the blood-brain barrier (BBB). It is unclear how intact the BBB is after complex aortic surgery, with massive inflammation, extra-corporeal circulation, and CNS ischemia. This is poorly investigated, but a small study suggests BBB disruption even after more standard cardiac surgery like aortic valve replacement \[[@CR25]\], which in turn makes it difficult to define the direction of flow between the compartments. There were multiple changes in the CSF levels of all operated patients, even the non-neurologically affected, which is interesting in itself. Further studies could perhaps link CSF alterations to later complications such as cognitive decline and decreased overall function \[[@CR9], [@CR10]\].

The study has some limitations, as for instance, the group with SCI is small. Also, two TEVAR patients are included; however, their postoperative samples were excluded so that potential effects of the ECC would be similar in all analyzed samples. Also, there is a possibility that subclinical strokes were missed \[[@CR29]\], as neuroimaging was not performed routinely, only upon clinical suspicion.

Conclusion {#Sec23}
==========

Several of the proteins differed between the neurologically affected and non-affected groups, and this is a source for further exploration and verification. However, it is not possible to conclude whether the alterations reflect intrinsic compensatory mechanisms, mediators of subsequent injury, and therefore potential target proteins for treatment or merely markers of damaged tissue. Even though the current study identifies new interesting markers, it needs confirmation and should ideally be complemented with mechanistic experiments.
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POD

:   postoperative day
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:   spinal cord injury

TAAA

:   thoraco-abdominal aortic aneurysm

TEVAR

:   thoracic endovascular aortic repair
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